|Table of Contents|

Meta-analysis of S-1 and non-S-1 based chemotherapy regimens in advanced gastric cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 06
Page:
994-998
Research Field:
Publishing date:

Info

Title:
Meta-analysis of S-1 and non-S-1 based chemotherapy regimens in advanced gastric cancer
Author(s):
ZENG Hai; XIE Qian; WANG Qian; LI Shuang; ZHANG Weijia
Department of Oncology,the First People's Hospital of Jingzhou,Hubei Jingzhou 434000,China.
Keywords:
advanced gastric cancer; S-1; chemotherapy; Meta-analysis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2021.06.018
Abstract:
Objective:To evaluate the safety and effect of S-1 based chemotherapy regimen in advanced gastric cancer by Meta-analysis.Methods:We searched the multicenter randomized control trials(mRCTs) comparing S-1 based chemotherapy to non-S-1 based chemotherapy regimens for advanced gastric cancer in electronic databases of CNKI,WANFANG,EmBase,Pubmed,up to December 1,2018.Primary outcome included objective response rate(ORR).Second outcome included median survival time(MST),time to progress(TTP) and adverse effects(AE).Results:Five mRCTs and 2 182 patients were included in this Meta-analysis.We found equivalent ORR of the S-1 based chemotherapy regimen and non-S-1 based chemotherapy regimen as the first-line treatment for advanced gastric cancer(33.67% vs 36.27%,RR=1.07,95%CI:0.91~1.26,P=0.42).S-1 based chemotherapy regimen had longer TTP than non-S-1 based chemotherapy regimen(5.1 months vs 4.3 months,P＝0.006),but no overall survival advantage(P＞0.05).Non-S-1 based chemotherapy regimen had more toxicities than S-1 based regimen,such as leucopenia(Ⅰ-Ⅳ,P＜0.000 1.Ⅲ-Ⅳ,P＜0.000 01),neutopenia(Ⅰ-Ⅳ,P＜0.000 01.Ⅲ-Ⅳ,P＜0.000 01),thrombcytopenia(Ⅰ-Ⅳ,P＜0.000 1.Ⅲ-Ⅳ,P=0.02),anorexia(Ⅲ-Ⅳ,P=0.002),nausea(Ⅰ-Ⅳ,P=0.009.Ⅲ-Ⅳ,P=0.000 2),vomiting(Ⅰ-Ⅳ,P=0.01),stomatitis(Ⅰ-Ⅳ,P＜0.000 01.Ⅲ-Ⅳ,P＜0.000 01).Conclusion:S-1 based chemotherapy regimen may be more attractive for gastric cancer patients for its non-inferior efficacy,better safety and more convenience compared with non-S-1 chemotherapy regimen.

References:

［1］SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2018 ［J］.CA Cancer J Clin,2018,68(1):7-30.
[2]MACHLOWSKA J,PUCULEK M,SITARZ M,et al.State of the art for gastric signet ring cell carcinoma:from classification,prognosis,and genomic characteristics to specified treatments ［J］.Cancer Manag Res,2019,11:2151-2161.
[3]ABDEL-RAHMAN O.Prognostic impact of baseline quality of life status among patients with advanced gastric cancer;results from two randomized studies ［J］.Expert Rev Pharmacoecon Outcomes Res,2019,22:1-5.
[4]KOIZUMI W,KURIHARA M,NAKANO S,et al.Phase II study of S-1,a novel oral derivative of 5-fluorouracil,in advanced gastric cancer.For the S-1 Cooperative Gastric Cancer Study Group ［J］.Oncology,2000,58(3):191-197.
[5]HUANG D,BA Y,XIONG J,et al.A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer ［J］.Eur J Cancer,2013,49(14):2995-3002.
[6]AJANI JA,RODRIGUEZ W,BODOKY G,et al.Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial ［J］.J Clin Oncol,2010,28(9):1547-1553.
[7]KIM GM,JEUNG HC,RHA SY,et al.A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer ［J］.Eur J Cancer,2012,48(4):518-526.
[8]LEE JL,KANG YK,KANG HJ,et al.A randomized multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer ［J］.Br J Cancer,2008,99(4):584-590.
[9]BOKU N,YAMAMOTO S,FUKUDA H,et al.Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomised phase 3 study ［J］.Lancet Oncol,2009,10(11):1063-1069.
[10]WLL E,THALER J,KEIL F,et al.Oxaliplatin/irinotecan/bevacizumab followed by docetaxel/bevacizumab in inoperable locally advanced or metastatic gastric cancer patients -a GMT_GASTRIC-3［J］.Anticancer Res,2017,37(10):5553-5558.
[11]WANG J,XU R,LI J,et al.Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer ［J］.Gastric Cancer，2016,19(1):234-244.
[12]NISHIMURA T,IWASA S,NAGASHIMA K,et al.Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines,platinum,and taxanes［J］.Gastric Cancer,2017,20(4):655-662.
[13]TER VEER E,NGAIL LL,VALKENHOEF GV,et al.Capecitabine,5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer:A network meta-analysis ［J］.Sci Rep,2017,7(1):7142.
[14]KANAJI S,SUZUKI S,MATSUDA Y,et al.Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer ［J］.Ann Gastroenterol Surg,2018,2(6):400-405.
[15]OUE N,SENTANI K,SAKAMOTO N,et al.Molecular carcinogenesis of gastric cancer:Lauren classification,mucin phenotype expression,and cancer stem cells ［J］.Int J Clin Oncol,2019,24(7):771-778.
[16]MAEDA O,MATSUOKA A,MIYAHARA R,et al.Modified docetaxel,cisplatin and capecitabine for stage IV gastric cancer in Japanese patients:A feasibility study［J］.World J Gastroenterol,2017,23(6):1090-1097.
[17]PLUMMER M,DE MARTEL C,VIGNAT J,et al.Global burden of cancers attributable to infections in 2012:a synthetic analysis ［J］.Lancet Glob Health,2016,4(9):e609-e616.
[18]MAHLBERG R,LORENZEN S,THUSS-PATIENCE P,et al.New perspectives in the treatment of advanced gastric cancer:S-1 as a novel oral 5-FU therapy in combination with cisplatin ［J］.Chemotherapy,2017,62(1):62-70.
[19]YANG L,ZOU S,SHU C,et al.CYP2A6 polymorphisms associate with outcomes of S-1 plus oxaliplatin chemotherapy in Chinese gastric cancer patients ［J］.Genomics Proteomics Bioinformatics,2017,15(4):255-262.

Memo

Memo:
-
Last Update: 1900-01-01